ELANCO ANIMAL HEALTH INC (ELAN)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for ELAN
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ELAN | President and CEO, Elanco Animal Health Incorporated; President and Chief Executive Officer | 58 | ["Business Leadership and Operations","Finance and Accounting","Global Business Experience","Public Company Board Experience","Business Leadership and Operations expertise","M&A and Business Development experience","Risk Management and Sustainability expertise","Research and Development/Innovation experience"] | ["Finance","Strategy and Oversight"] | 2026 |
Biography sourced from the proxy statement filing.
Age: 58 Director Since: September 2018 BOARD COMMITTEES Finance, Strategy and Oversight Chief Executive Officer, Elanco Animal Health Incorporated (since 2018) Eli Lilly and Company , a global pharmaceutical company (1989 2018) - Senior Vice President and President of the Elanco Animal Health division at Lilly (2008 2018) - Held various leadership roles in the Elanco Animal Health division, including International Marketing Manager, Country Director for Brazil, Area Director for Western Europe and Executive Director for U.S. and Global Research & Development KEY QUALIFICATIONS Business Leadership and Operations expertise exhibited as a proven, purpose-driven leader during his 30-plus years in the life sciences industry, including as the head of Elanco for the past decade, during which he directed Elanco's growth and transformation from a primarily U.S. livestock feed additive company to a global animal health leader with a diversified business, more than quadrupled revenue, created a unique innovation engine and built five new businesses, including a greater than $2 billion pet health business M&A and Business Development experience acquired while evaluating, executing and integrating several significant acquisitions during his tenure as Elanco s CEO, including the acquisitions of Aratana Therapeutics, Kindred Biosciences and Bayer Animal Health, one of the largest animal health transactions to date Risk Management and Sustainability expertise shown as Elanco has demonstrated its commitment to sustainability, including through its commercialization and advancement of Bovaer , Elanco's methane reduction product, and its development of a carbon insetting marketplace Research and Development/Innovation experience acquired through his oversight of research and development programs over the past three decades, including the successful product launch of numerous animal health blockbuster drugs while serving as Executive Director for U.S. and Global Research & Development as well as other senior leadership roles within the Elanco Animal Health Division of Lilly